The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions
Open accessAbstract
BACKGROUND: The prognostic importance of high-density lipoprotein cholesterol (HDL-C) as a specific risk factor for cardiovascular (CV) disease has been challenged by recent clinical trials and genetic studies. OBJECTIVES: This study sought to reappraise the association of HDL-C level with CV and non-CV mortality using a "big data" approach. METHODS: An observational cohort study was conducted using the CANHEART (Cardiovascular Health in Ambulatory Care Research Team) dataset, which was created by linking together 17 different individual-level data sources. People were included if they were between 40 and 105 years old on January 1, 2008, living in Ontario, Canada, without previous CV conditions or severe comorbidities, and had an outpatient fasting cholesterol measurement in the year prior to the inception date. The primary outcome was cause-specific mortality. RESULTS: A total of 631,762 individuals were included. The mean age of our cohort was 57.2 years, 55.4% were women, and mean HDL-C level was 55.2 mg/dl. There were 17,952 deaths during a mean follow-up of 4.9 ± 0.4 years. The overall all-cause mortality rate was 8.1 per 1,000 person-years for men and 6.6 per 1,000 person-years for women. Individuals with lower HDL-C levels were more likely to have low incomes, unhealthy lifestyle, higher triglycerides levels, other cardiac risk factors, and medical comorbidities. Individuals with lower HDL-C levels were independently associated with higher risk of CV, cancer, and other mortality compared with individuals in the reference ranges of HDL-C levels. In addition, individuals with higher HDL levels (>70 mg/dl in men, >90 mg/dl in women) had increased hazard of non-CV mortality. CONCLUSIONS: Complex associations exist between HDL-C levels and sociodemographic, lifestyle, comorbidity factors, and mortality. HDL-C level is unlikely to represent a CV-specific risk factor given similarities in its associations with non-CV outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 1×
“For example, studies have shown that each 1 mg/dl increase in HDL-C level was associated with 3% to 4% lower rates of death from cardiac causes (2,5,6), suggesting that attainment of higher levels of HDL-C may reduce the risk of CV events.”
BackgroundHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162 · cited 1×
“For example, studies have shown that each 1 mg/dl increase in HDL-C level was associated with 3% to 4% lower rates of death from cardiac causes (2,5,6), suggesting that attainment of higher levels of HDL-C may reduce the risk of CV events.”
BackgroundEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels: The Framingham Study
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.1986.03380200073024 · Cited by 1,611
Competing Risk Regression Models for Epidemiologic Data
Lau, B., Cole, S. R., & Gange, S. J. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp107 · Cited by 1,403
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Grundy, S. M., Pasternak, R., Greenland, P., Smith, S., & Fuster, V. (1999) · Circulation · doi:10.1161/01.cir.100.13.1481 · Cited by 1,315
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870 · cited 1×
“Recent studies have cast doubts about the prognostic importance of HDL-C level as a modifiable risk factor (3,16,24).”
BackgroundSafety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
High density lipoprotein cholesterol and mortality. The Framingham Heart Study.
Wilson, P. W., Abbott, R. D., & Castelli, W. P. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.6.737 · Cited by 644
Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction
Wolbers, M., Koller, M. T., Witteman, J. C. M., & Steyerberg, E. W. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a39056 · Cited by 625
KANNEL, W. B., DAWBER, T. R., FRIEDMAN, G. D., GLENNON, W. E., & MCNAMARA, P. M. (1964) · Annals of Internal Medicine · doi:10.7326/0003-4819-61-5-888 · Cited by 536
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336 · cited 2×
“Moreover, associations are known between HDL-C level and other demographic and lifestyle factors, such as smoking, obesity, and limited physical activity (2).”
BackgroundAustin, P. C., van Walraven, C., Wodchis, W. P., Newman, A., & Anderson, G. M. (2011) · Medical Care · doi:10.1097/mlr.0b013e318215d5e2 · Cited by 326
Self-citationMcPherson, R., Frohlich, J., Fodor, G., & Genest, J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70310-5 · Cited by 308
Ridker, P. M., Genest, J., Boekholdt, S. M., Libby, P., Gotto, A. M., Nordestgaard, B. G., Mora, S., MacFadyen, J. G., Glynn, R. J., & Kastelein, J. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60713-1 · Cited by 256
Tu, J. V., Chu, A., Donovan, L. R., Ko, D. T., Booth, G. L., Tu, K., Maclagan, L. C., Guo, H., Austin, P. C., Hogg, W., et al. (2015) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.001416 · Cited by 187
Self-citationTu, J. V., Chu, A., Rezai, M. R., Guo, H., Maclagan, L. C., Austin, P. C., Booth, G. L., Manuel, D. G., Chiu, M., Ko, D. T., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015345 · Cited by 136
Self-citationCoronary Heart Disease Risks Associated with High Levels of HDL Cholesterol
Wilkins, J. T., Ning, H., Stone, N. J., Criqui, M. H., Zhao, L., Greenland, P., & Lloyd‐Jones, D. M. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000519 · Cited by 129
Self-citationHigh-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht343 · Cited by 123
Angeloni, E., Paneni, F., Landmesser, U., Benedetto, U., Melina, G., Lüscher, T. F., Volpe, M., Sinatra, R., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht163 · Cited by 79
HDL cholesterol and mortality in Finnish men with special reference to alcohol intake.
Paunio, M., Heinonen, O. P., Virtamo, J. R. K., Klag, M. J., Manninen, V., Albanes, D., & Comstock, G. W. (1994) · Circulation · doi:10.1161/01.cir.90.6.2909 · Cited by 75
Niacin and HDL Cholesterol — Time to Face Facts
Lloyd‐Jones, D. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1406410 · Cited by 48
Jekyll and Hyde of HDL: a lipoprotein with a split personality
Shah, P. K. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht382 · Cited by 13
Cited by
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Self-citationBorén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx163 · Cited by 715
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
High-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401
Metadata
- Authors
- Ko, D. T., Alter, D. A., Guo, H., Koh, M., Lau, G., Austin, P. C., Booth, G. L., Hogg, W., Jackevicius, C. A., Lee, D. S., Wijeysundera, H. C., Wilkins, J. T., & Tu, J. V.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 68
- Issue
- 19
- Pages
- 2073-2083
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2546994911
- Cited by
- 340
- References
- 27
- FWCI
- 31.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.